Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 255

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 255
---
3, forfeitures resulting in the reversal of compensation expenses were immaterial.As of December 31, 2024, the unrecognized compensation cost related to options was $65.1 million, and is expected to be recognized as expense over a weighted-average period of approximately 2.5 years.

8. Net Loss Per ShareThe following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): 

        Year EndedDecember 31,

        2024

        2023

        Numerator:

        Net loss
         
        $
        (86,481
        )
         
        $
        (69,134
        )

        Denominator:

        Weighted-average common shares outstanding

        57,250,061

        42,882,832

        Less: weighted-average unvested restricted common stock subject to repurchase

        —

        (2,393
        )

        Less: weighted-average unvested common stock issued upon early exercise of common stock options

        (32,315
        )

        (175,563
        )

        Weighted-average shares used to compute net loss per common share, basic and diluted

        57,217,746

        42,704,876

        Net loss per share, basic and diluted
         
        $
        (1.51
        )
         
        $
        (1.62
        )
       
      Included in the weighted-average shares of common stock outstanding, both basic and diluted for the year ended December 31, 2024 are weighted shares of common stock issuable upon the exercise of the 2024 Pre-Funded Warrants and the Exchange Warrants (described in Note 6). The 2024 Pre-Funded Warrants and the Exchange Warrants are exercisable at any time for nominal consideration, and therefore, these shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive. 

        As of December 31,

        2024

        2023

        Unvested common stock upon early exercise of stock options

        4,317

        74,421

        Options to purchase common stock

        10,462,129

        8,276,442

        Estimated shares purchas